Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,747 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Vélez ID, Hien TT, Green JA, Martin A, Sharma H, Rousell VM, Breton JJ, Ernest TB, Rolfe K, Taylor M, Mohamed K, Jones SW, Chau NH, Hoa NT, Duparc S, Tan LK, Goyal N. Vélez ID, et al. Among authors: taylor m. Lancet Child Adolesc Health. 2022 Feb;6(2):86-95. doi: 10.1016/S2352-4642(21)00328-X. Epub 2021 Dec 3. Lancet Child Adolesc Health. 2022. PMID: 34871570 Clinical Trial.
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
Green JA, Mohamed K, Goyal N, Bouhired S, Hussaini A, Jones SW, Koh GC, Kostov I, Taylor M, Wolstenholm A, Duparc S. Green JA, et al. Among authors: taylor m. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7321-7332. doi: 10.1128/AAC.01588-16. Print 2016 Dec. Antimicrob Agents Chemother. 2016. PMID: 27697758 Free PMC article. Clinical Trial.
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL, Xue Z, Carter N, Koh GC, Duparc S, Taylor M, Beaumont C, Llanos-Cuentas A, Rueangweerayut R, Krudsood S, Green JA, Rubio JP. St Jean PL, et al. Among authors: taylor m. Malar J. 2016 Feb 18;15:97. doi: 10.1186/s12936-016-1145-5. Malar J. 2016. PMID: 26888075 Free PMC article. Clinical Trial.
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.
Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Elliott RL, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM. Blackie JA, et al. Among authors: taylor ma. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2603-6. doi: 10.1016/s0960-894x(02)00473-0. Bioorg Med Chem Lett. 2002. PMID: 12182870
9,747 results